Charles Davis came to Tango from the Novartis Institutes for BioMedical Research (NIBR), where he served as vice president, PK sciences. At NIBR, he led an international team of scientists representing the PKS discipline on more than 100 projects and was a member of the PKS Leadership Team, the Integrated Cancer Board and the Oncology Development Leadership Team. Before joining Novartis, Charles spent more than 20 years at GlaxoSmithKline, where he served on the leadership teams of three of GSK’s Centers of Excellence in Drug Discovery.
Charles has a Bachelor of Arts in chemistry from Swarthmore College and a doctorate in biophysical chemistry from Cornell University. At Tango, he is responsible for Drug Metabolism and Pharmacokinetics (DMPK), safety assessment and clinical pharmacology.